{
  "source": "PA-Notification-Lorbrena.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1267-7\nProgram Prior Authorization/Notification\nMedication Lorbrena® (lorlatinib)\nP&T Approval Date 12/2018, 12/2019, 12/2020, 2/2022, 2/2023, 2/2024, 2/2024\nEffective Date 5/1/2025\n1. Background:\nLorbrena (lorlatinib) is a kinase inhibitor indicated for the treatment of adult patients with\nanaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).\nIn addition, the National Cancer Comprehensive Network (NCCN) recommends Lorbrena for the\ntreatment of patients with ALK-positive recurrent and advanced NSCLC and in patients with\nROS1 rearrangement positive recurrent, advanced, or metastatic NSCLC.\nThe use of Lorbrena is also recommended by the NCCN for the treatment of Erdheim-Chester\nDisease (ECD) with symptomatic or relapsed/refractory disease, treatment of advanced,\nrecurrent/metastatic, or inoperable uterine sarcoma, treatment of limited and extensive brain\nmetastases in patients with ALK rearrangement-positive NSCLC, treatment of inflammatory\nmyofibroblastic tumor (IMT) with ALK translocation, and treatment of relapsed or refractory\nALK-positive peripheral T-Cell and large B-Cell lymphoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Lorbrena will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-small cell lung cancer (NSCLC)\n1. Initial Authorization\na. Lorbrena will be approved ",
    "he following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-small cell lung cancer (NSCLC)\n1. Initial Authorization\na. Lorbrena will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of NSCLC\n-AND-\n(2) One of the following:\n(a) Disease is both of the following:\ni. Recurrent, advanced, or metastatic\nii. Anaplastic lymphoma kinase (ALK)-positive\n-OR-\n(b) Both of the following:\ni. Disease is both of the following:\n• Advanced, metastatic, or recurrent\n• ROS proto-oncogene 1 (ROS1)-positive\n-AND-\nii. Disease has progressed on at least one of the following therapies:\n• Augtyro (repotrectinib)\n• Rozlytrek (entrectinib)\n• Xalkori (crizotinib)\n• Zykadia (ceritinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lorbrena will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lorbrena\ntherapy\nAuthorization will be issued for 12 months.\nC. Histiocytic Neoplasms\n1. Initial Authorization\na. Lorbrena will be approved based on the following criteria:\n(1) Diagnosis of Erdheim-Chester Disease (ECD)\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(2) Disease is both of the following:\n(a) Symptomatic, relapsed, or refractory\n-AND-\n(b) ALK-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lorbrena will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lorbrena\ntherapy\nAuthorization will be issued for 12 months.\nD. Soft Tissue Sarcoma\n1. Initial Authorization\na. Lorbrena will be approved based on the following criteria:\n(1) Diagnosis of inflammatory myofibroblastic tumor (IMT)\n-AND-\n(2) Disease is ALK-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lorbrena will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lorbrena\nthe",
    "rization will be issued for 12 months.\n2. Reauthorization\na. Lorbrena will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lorbrena\ntherapy\nAuthorization will be issued for 12 months.\nE. Uterine Sarcoma\n1. Initial Authorization\na. Lorbrena will be approved based on the following criteria:\n(1) Diagnosis of uterine sarcoma\n© 2025 UnitedHealthcare Services, Inc.\n3\n-AND-\n(2) Disease is one of the following:\n(a) Advanced\n(b) Recurrent/metastatic\n(c) Inoperable\n-AND-\n(3) Disease is ALK-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lorbrena will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Lorbrena\ntherapy\nAuthorization will be issued for 12 months.\nF. Lymphoma\n1. Initial Authorization\na. Lorbrena will be approved based on the following criteria:\n(1) One of the following diagnoses:\n(a) Anaplastic large cell lymphoma (ALCL)\n-OR-\n(b) Large B-Cell lymphoma\n-AND-\n(2) Disease is relapsed or refractory\n-AND-\n(3) Disease is ALK-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Lorbrena will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n4\n(1) Patient does not show evidence of progressive disease while on Lorbrena\ntherapy\nAuthorization will be issued for 12 months.\nG. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nautho",
    "t coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Lorbrena [package insert]. New York, NY: Pfizer Labs; April 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed December 20,\n2024.\nProgram Prior Authorization/Notification – Lorbrena (lorlatinib)\nChange Control\n12/2018 New program.\n12/2019 Updated criteria according to NCCN guidelines. Added general NCCN\nrecommendations for use criteria. Updated background and references.\n12/2020 Annual review. Updated background and criteria to reflect NCCN\nguidance. Updated references.\n2/2022 Annual review. Updated background and criteria to reflect updated\nNSCLC indication and NCCN guidelines. Updated references.\n2/2023 Annual review. Updated background and coverage criteria to reflect\nupdated NCCN guidelines. Added state mandate footnote and updated\nNCCN reference.\n2/2024 Annual review. Added criteria for NCCN recommended use of\nLorbrena in uterine sarcoma, peripheral T-Cell lymphoma and large B-\ncell lymphoma. Updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n5\n2/2025 Annual review. Added Augtyro (repotrectinib) as a first-line therapy\noption for ROS1 positive NSCLC per NCCN. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}